PRESS RELEASE published on 12/18/2024 at 07:30, 1 year 10 months ago Inside Information / Other news releases Sensorion reports positive safety data and behavioral changes in toddlers from the Audiogene Phase 1/2 Gene Therapy Clinical Trial. Plans KOL event in 2025 for further discussion Gene Therapy Clinical Trial Sensorion Hearing Loss Audiogene
BRIEF published on 11/06/2024 at 07:35, 1 year 11 months ago Sensorion to Join Key Investor Conferences in November 2024 Biotechnology Investor Conferences Sensorion Hearing Loss Therapies Gene Therapy Development
PRESS RELEASE published on 11/06/2024 at 07:30, 1 year 11 months ago Inside Information / Other news releases Sensorion to participate in upcoming investor conferences in November 2024, including Stifel Healthcare Conference and LifeSci Capital & Sofinnova Partners Summit Biotechnology Investor Conferences Clinical-stage Sensorion Hearing Loss Disorders
BRIEF published on 09/20/2024 at 07:35, 2 years 1 month ago Sensorion Unveils Promising New Clinical Advances Biotechnology Clinical Trials Gene Therapy Hearing Loss Small Molecule
PRESS RELEASE published on 09/20/2024 at 07:30, 2 years 1 month ago Inside Information / Other news releases Sensorion announces positive clinical data on gene therapy and small molecule programs at World Congress of Audiology, Paris. Details by key medical professionals Clinical Data Gene Therapy Sensorion World Congress Of Audiology Small Molecule
BRIEF published on 09/18/2024 at 07:35, 2 years 1 month ago Sensorion Reports First Half 2024 Financial Results and Clinical Advances Clinical Trials Gene Therapy 2024 Financial Results Sensorion Hearing Loss Therapies
PRESS RELEASE published on 09/18/2024 at 07:30, 2 years 1 month ago Half yearly financial reports and audit reports/limited reviews / Half yearly financial report Sensorion reports 2024 first half results including progress on SENS-501 and SENS-401 programs. Cash position strong at €87m. Future milestones and financial highlights outlined Sensorion Hearing Loss SENS-401 SENS-501 2024 Results
BRIEF published on 09/12/2024 at 07:35, 2 years 1 month ago Sensorion to Present at 59th Inner Ear Biology Workshop Conference Sensorion Hearing Loss Inner Ear Biology Proteomics
PRESS RELEASE published on 09/12/2024 at 07:30, 2 years 1 month ago Inside Information / Other news releases Sensorion announces participation in the 59th Annual Inner Ear Biology Workshop in Warsaw, Poland. Presentation on SENS-401 and gene therapy programs Gene Therapy Sensorion Hearing Loss SENS-401 Inner Ear Biology Workshop
BRIEF published on 09/02/2024 at 07:35, 2 years 2 months ago Sensorion at the World Congress of Audiology 2024 in Paris Gene Therapy Sensorion Hearing Loss World Congress Of Audiology Medical Symposium
Published on 11/02/2026 at 15:00, 1 hour 18 minutes ago CSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference in Dubai (UAE)
Published on 11/02/2026 at 14:00, 2 hours 18 minutes ago GameSquare to Report Q3 2026 Financial Results on November 16, 2026
Published on 11/02/2026 at 14:00, 2 hours 18 minutes ago Tectonic Metals Intersects 5.61 g/t Au Over 41.15 m, Including 12.94 g/t Au Over 13.72 m, Within 2.86 g/t Au Over 91.44 m, Strengthening Evidence for a Second Gold System at the Flat Gold Project
Published on 11/02/2026 at 13:30, 2 hours 48 minutes ago Electric Metals (USA) Limited Announces Results of Annual Meeting of Stockholders
Published on 11/02/2026 at 13:30, 2 hours 48 minutes ago Predictiv AI Awarded Metrolinx Master Agreement for On-Demand Transit Software and Related Services
Published on 11/02/2026 at 15:58, 20 minutes ago Original-Research: Deutsche Rohstoff AG (von First Berlin Equity Research GmbH): Buy
Published on 11/02/2026 at 15:19, 59 minutes ago Form 8.3 - The Vanguard Group, Inc.: RHI Magnesita N.V.
Published on 11/02/2026 at 15:25, 52 minutes ago Guillemot Corporation S.A. | Information regarding the total number of voting rights and shares 31/10/2026
Published on 10/30/2026 at 23:00, 2 days 17 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 18:00, 2 days 22 hours ago 2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 3 days 4 hours ago Capital increase through exercise of subscription rights
